Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Inclusion Criteria

• •Histologically or cytologically confirmed relapsed or refractory non-Hodgkin lymphoma for which standard curative or palliative measures do not exist or are no longer effective, including any of the following subtypes:
• •* Follicular grade I, II, or III lymphoma
• •* Marginal zone lymphoma
• •* Mantle cell lymphoma
• •* Diffuse large B cell lymphoma
• •* Small lymphocytic lymphoma
• •Must have had at least one prior chemotherapeutic regimen:
• •* Steroids or rituximab alone or local radiotherapy do not count as regimens
• •* Tositumomab or ibritumomab tiuxetan allowed as regimens
• •Clear evidence of disease progression or lack of response after the most recent therapy, including rituximab or local radiotherapy, is required
• •At least 3 months since prior autologous stem cell transplantation and relapsed (\>= 1 year since prior allogeneic transplantation and relapsed) and no active related infections (i.e., fungal or viral)
• •In the case of allogeneic transplantation relapse, there should be no active acute graft-versus-host disease (GVHD) of any grade and no chronic GVHD other than mild skin, oral, or ocular GVHD not requiring systemic immunosuppression
• •No known active brain metastases, other neurological disorders/dysfunction or history of seizure disorder, or other neurological dysfunction
• •Karnofsky performance status 60-100%
• •Life expectancy \> 3 months
• •Total bilirubin normal
• •AST and ALT =\< 2.5 times upper limit of normal
• •Creatinine normal or creatinine clearance \>= 60 mL/min
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective double-barrier contraception during and for 3 months after the last dose of obatoclax mesylate
• •At least 4 weeks since prior radiotherapy
• •More than 2 days since prior steroids
• •More than 2 weeks since prior low-dose chlorambucil
• •WBC \>= 3,000/mm\^3
• •ANC \>= 1,500/mm\^3
• •Platelet count \>= 100,000/mm\^3
• •At least 2 weeks since prior valproic acid